GURU.Markets stock price, segment price, and overall market index valuation
The company's share price KalVista Pharmaceuticals
Shares of KalVista, a biopharmaceutical company focused on treating hereditary angioedema, reflect the potential of its oral drug. The price chart is a story of investors' hopes for a convenient alternative to injectable treatments.
Share prices of companies in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare inflammatory diseases, such as hereditary angioedema. We have classified the company in the Pharma: Immunology category. The chart below shows the dynamics of the orphan disease sector.
Broad Market Index - GURU.Markets
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare inflammatory diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
KALV - Daily change in the company's share price KalVista Pharmaceuticals
Shares of KalVista, a biopharmaceutical company, are exhibiting the extreme volatility typical of the sector. change_co tracks investor reactions to clinical trial news. This parameter is key for building high-risk asset valuation models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
KalVista Pharmaceuticals, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with KALV, a rare disease company, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
KalVista is a biopharmaceutical company specializing in drugs for the treatment of rare diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing KalVista's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization KalVista Pharmaceuticals
KalVista is a biopharmaceutical company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
KalVista Pharmaceuticals, Inc. is a late-stage biotech company developing oral therapies for rare diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
KalVista is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization KalVista Pharmaceuticals
InnovAge, a company providing comprehensive in-home care for seniors through the PACE program, is a leading provider of care. The monthly fluctuations in the graph reflect the number of program participants. Government reimbursement rates and changes in healthcare policy are also important factors.
Monthly dynamics of market capitalization of the market segment - Pharma immune
KalVista Pharmaceuticals is working on a treatment for rare diseases associated with hereditary angioedema. The biotech sector, to which it belongs, is extremely sensitive to news about clinical trials. Industry dynamics reflect investors' faith in scientific breakthroughs, and KalVista's story is a bet on one such potential breakthrough.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
KalVista Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of hereditary angioedema (HAE). The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its potential to develop convenient therapies impacted its stock price.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biotech company developing drugs to treat rare diseases. Its weekly stock price is highly volatile and dependent on clinical trial news, as is typical for this sector.
Weekly dynamics of market capitalization of the market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company. Comparing its weekly performance to the broader biotech sector only highlights its uniqueness. The chart shows how news about clinical trials of its drugs drives share prices independent of overall trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of KalVista, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how its stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
KALV - Market capitalization of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals' market capitalization chart is a focused bet on a new treatment for hereditary angioedema (HAE). Its performance reflects investors' hopes for an oral drug that could change patients' lives. It's a classic biotech story, where the success of one product determines everything.
KALV - Share of the company's market capitalization KalVista Pharmaceuticals within the market segment - Pharma immune
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company specializing in the development of oral therapies for the treatment of hereditary angioedema (HAE) and other rare diseases. Its market share reflects the potential of its innovative treatments. The chart below demonstrates the market's confidence in its science.
Market capitalization of the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing oral therapies for the treatment of hereditary angioedema. The chart below shows the overall market capitalization of the immunopharmaceuticals sector, reflecting the company's commitment to creating more convenient treatments for patients with rare diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the fight against a rare genetic disease. KalVista Pharmaceuticals is developing an oral drug to treat hereditary angioedema. Its volatile line on the chart reflects news from the clinic, visualizing hope for a more convenient treatment for patients.
Book value capitalization of the company, segment and market as a whole
KALV - Book value capitalization of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals' foundation is its intellectual property for oral medications for the treatment of hereditary angioedema and its financial reserves. This represents focused scientific capital. The chart shows how the biotech company manages its research budget during the process of bringing its lead drug candidate to market.
KALV - Share of the company's book capitalization KalVista Pharmaceuticals within the market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company developing drugs for the rare disease hereditary angioedema. Its assets are intellectual property. The chart shows a minimal share of physical assets, as it is an R&D company.
Market segment balance sheet capitalization - Pharma immune
Developing drugs for rare diseases, like KalVista's, is a knowledge-intensive but relatively "easy" business at the R&D stage. Its value lies in its patents. Compared to the capital-intensive pharmaceutical sector, the company's model doesn't require the ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
KalVista Pharmaceuticals' assets are not factories, but capital allocated to clinical trials of oral drugs for the treatment of a rare genetic disease, hereditary angioedema. These assets reflect its financial resources for development. The chart illustrates the scale of this focused biotech company.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - KalVista Pharmaceuticals
For KalVista, which is developing a drug for a rare disease, market capitalization represents the belief in the success of its core product. Its ratio to book value (its cash value) reflects how much investors are willing to pay for the potential to become a standard treatment in its niche.
Market to book capitalization ratio in a market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company developing drugs to treat rare diseases. Its high valuation on this chart reflects the success of its lead drug. This is a binary outcome, typical of biotech, where clinical data is everything.
Market to book capitalization ratio for the market as a whole
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral medications for the rare disease hereditary angioedema. Its valuation is a bet that its convenient tablet will be competitive with injectable medications. This metric reflects a premium on innovations that improve patients' quality of life.
Debts of the company, segment and market as a whole
KALV - Company debts KalVista Pharmaceuticals
KalVista, a clinical-stage biopharmaceutical company, is raising capital to develop drugs for rare diseases. Its survival and success depend entirely on its ability to fund lengthy and expensive research. This chart shows how the company uses equity and debt capital to achieve its scientific goals.
Market segment debts - Pharma immune
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of hereditary angioedema (HAE). This chart shows how the company is funding its expensive clinical trials, aiming to offer patients a more convenient alternative to existing injectable treatments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of small molecules for the treatment of rare diseases, such as hereditary angioedema. Clinical trials are a lengthy and very expensive process. This chart illustrates the company's reliance on debt to finance its high-risk research.
Market segment debt to market segment book capitalization - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat hereditary angioedema and other rare diseases. This chart shows how the company finances its expensive clinical trials, comparing its debt structure to the overall financial picture in the biotech sector.
Debt to book value of all companies in the market
KalVista Pharmaceuticals develops drugs to treat rare diseases such as hereditary angioedema. Biotechnology requires massive investment in research. How heavily does the company rely on debt? This chart of total market debt allows us to assess its financial strategy and the risks involved in the long road to commercialization.
P/E of the company, segment and market as a whole
P/E - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema (HAE). This chart shows how investors assess its chances of offering a more convenient alternative to injectable treatments. This assessment is heavily dependent on the results of clinical trials.
P/E of the market segment - Pharma immune
KalVista Pharmaceuticals is a clinical-stage pharmaceutical company specializing in the development of oral protease inhibitors for the treatment of hereditary angioedema and other diseases. This chart shows the average valuation for the sector, providing investors with context for assessing KalVista's scientific potential and niche strategy.
P/E of the market as a whole
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company developing oral therapies for the rare disease hereditary angioedema. The company's valuation is in a world of its own, dependent on the success of clinical trials. How insulated is it from overall market sentiment, a pure bet on science?
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema (HAE). This chart reflects market expectations for the success of its drugs. Future revenue depends on regulatory approval and the company's ability to compete with existing injectable treatments.
%20P%2FE%20KalVista%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-KalVista-Pharmaceuticals&v=1772513833596 "Chart of the company's future (projected) P/E KalVista Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral medications for the treatment of hereditary angioedema (HAE) and other rare diseases. The chart shows industry forecasts. This helps compare how the market perceives the potential of KalVista's medications to change the standard of care for HAE compared to injectable therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513833632 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
KalVista Pharmaceuticals is a biopharmaceutical company developing treatments for rare diseases such as hereditary angioedema. Its valuation depends on the success of its lead drug. This market sentiment graph influences how investors evaluate biotech companies approaching commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513833647 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medications for the rare disease hereditary angioedema. While in the clinical stage, the company is incurring losses. This chart illustrates the financial implications of developing drugs for orphan diseases, which carry high risks but also the potential for success.
Profit of companies in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral medications for rare diseases such as hereditary angioedema. This chart, which reflects the pharmaceutical sector's profitability, highlights the investment climate. Their goal is to offer patients a convenient alternative to injections, and success depends on the results of clinical trials.
Overall market profit
KalVista Pharmaceuticals specializes in developing oral medications for the treatment of hereditary angioedema and other rare diseases. The company's success depends on the results of clinical trials. This overall market return chart reflects the investment climate, which is critical for biotech companies that require consistent funding for their expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral therapies for the treatment of hereditary angioedema (HAE) and other rare diseases. This chart represents analyst consensus forecasts for clinical trial success and potential commercial market penetration for injectable therapies.
%20profit%20of%20the%20company%20KalVista%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-KalVista-Pharmaceuticals&v=1772513833718 "Graph of future (projected) profit of the company KalVista Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing protease inhibitors for the treatment of hereditary angioedema and other diseases. Its future depends on the success of clinical trials and the commercialization of its drugs. This biotech chart reflects the overall market expectations for innovative treatments for rare diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513833779 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
KalVista Pharmaceuticals develops drugs to treat rare diseases. Its value is determined by research success. However, the overall economic situation, reflected in this forecast, influences the investment climate. In good times, investors are more willing to fund biotech, which is important for continued development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513833826 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company developing protease inhibitors for the treatment of rare diseases such as hereditary angioedema. This chart is crucial because it provides an estimate of future sales. Investors are betting on the success of its oral medications, which could change the standard of care.
P/S market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medications for rare diseases such as hereditary angioedema. The company's valuation is based on the future potential of its innovative drugs. This chart reflects the average valuation in the sector, helping to understand investor expectations for KalVista's developments.
P/S of the market as a whole
KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for the treatment of hereditary angioedema and other rare diseases. This chart, which reflects market revenue estimates, serves as a measure of KalVista's hopes. It demonstrates the value investors place on the potential of creating a convenient treatment for patients.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biotech company developing small-molecule inhibitors for the treatment of hereditary angioedema and other rare diseases. This chart reflects investor expectations for the future commercial success of its oral medications, which could become a convenient alternative to injections.
%20P%2FS%20KalVista%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-KalVista-Pharmaceuticals&v=1772513833938 "The graph of the company's future (projected) P/S KalVista Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma immune
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral protease inhibitors for the treatment of rare diseases. This chart reflects average revenue expectations in the biotech sector. It provides an insight into the market perception of the potential of KalVista's innovative drugs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513834001 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral medications for the treatment of rare diseases such as hereditary angioedema. This chart shows investor expectations for revenue growth. KalVista's success could offer patients a more convenient alternative to injections, creating a new standard of care.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513834018 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales KalVista Pharmaceuticals
This chart shows the revenue of KalVista Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing oral therapies for rare diseases such as hereditary angioedema. Its revenue, when it has any, is generated through partnerships, reflecting research progress.
Sales of companies in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other conditions. This graph shows the potential market for treating rare diseases. If successful, KalVista's drugs could offer patients a convenient and effective alternative to injectable treatments.
Overall market sales
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases. Its value depends on progress in clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to invest in the biotech sector, with its high risks and potential.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company developing treatments for hereditary angioedema and other rare diseases. Its revenue projections are based on expectations of successful clinical trials and the market launch of its oral medications.
%20sales%20of%20the%20company%20KalVista%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-KalVista-Pharmaceuticals&v=1772513834181 "Schedule of future (projected) sales of the company KalVista Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing oral protease inhibitors for the treatment of hereditary angioedema (HAE) and other rare diseases. This chart shows the forecast for the entire pharmaceutical market, where KalVista aims to offer patients with HAE a convenient and effective alternative to injectable medications.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513834194 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
KalVista Pharmaceuticals develops drugs to treat rare diseases, particularly hereditary angioedema. Its success depends on clinical data and regulatory approval. This chart illustrates general market sentiment, but for KalVista, proving its product's efficacy and safety in a specific patient population is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513834228 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biotech company developing inhibitors for the treatment of hereditary angioedema and other diseases. Being in the clinical stage, it incurs significant research expenses. This chart shows its net losses—investments in developing targeted drugs for rare but serious diseases.
Market segment marginality - Pharma immune
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral therapies for the treatment of hereditary angioedema (HAE) and other conditions. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors evaluate it in the context of the potential to transform the treatment of HAE.
Market marginality as a whole
KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral medications for rare diseases, primarily hereditary angioedema. This overall profitability curve is not directly relevant to them. Their market capitalization depends entirely on the success of their clinical programs and the market potential of their drugs.
Employees in the company, segment and market as a whole
Number of employees in the company KalVista Pharmaceuticals
KalVista Pharmaceuticals is a clinical-stage biotech company developing oral medications for rare diseases. Its small team is focused on R&D. Growth on this chart indicates progress in clinical trials and preparation for potential market entry.
Share of the company's employees KalVista Pharmaceuticals within the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare diseases, particularly hereditary angioedema. This chart shows its share of the total number of researchers in this niche area. The growth in this percentage reflects progress in clinical trials and the expansion of the scientific team working on the development of life-saving drugs.
Number of employees in the market segment - Pharma immune
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral protease inhibitors for the treatment of rare diseases. This chart shows employment trends in the drug development sector. The growth in the number of scientists and clinicians is directly related to progress in clinical trials and the approach to potential product commercialization.
Number of employees in the market as a whole
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of oral therapies for the treatment of a rare genetic disorder, hereditary angioedema. This achievement demonstrates how focusing on orphan diseases enables small biotech companies to create breakthrough innovations and stimulate scientific employment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals is a biotech company specializing in drugs for hereditary angioedema. This chart is a classic example of intellectual capital valuation. The company's value is based on the expectations for its drug candidates. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20KalVista%20Pharmaceuticals%20(KALV)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-KalVista-Pharmaceuticals-KALV&v=1772513834435 "Chart of market capitalization per employee (in thousands of dollars) of the company KalVista Pharmaceuticals (KALV)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of protease inhibitors for the treatment of rare diseases. Its value is determined by its scientific platform and clinical trial results. This chart shows the high valuation of its intellectual property based on its small team of scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513834460 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
KalVista Pharmaceuticals is a biopharmaceutical company developing drugs to treat inflammation-related diseases, particularly hereditary angioedema. The chart reflects an assessment of scientific potential. The company's entire value is derived from the hope of successful clinical trials.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513834484 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals is a clinical-stage biotech company specializing in developing oral medications (in tablet form) for the treatment of rare diseases such as hereditary angioedema. This is R&D. This chart shows the company's capital burn: the amount of capital the company spends on each scientist during expensive clinical trials.
%20Chart%20KalVista%20Pharmaceuticals%20(KALV)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-KalVista-Pharmaceuticals-KALV&v=1772513834501 "Company Profit Per Employee (in thousands of dollars) Chart KalVista Pharmaceuticals (KALV)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
KalVista Pharmaceuticals (KALV) is a clinical-stage biotechnology company developing oral therapies for the rare disease hereditary angioedema (HAE). This loss per employee reflects the high costs of R&D and clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513834518 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
KalVista Pharmaceuticals is a clinical-stage biotech company specializing in the treatment of hereditary angioedema (a competitor to Pharvaris). It's an R&D company and has no profit. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513834531 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals is a biopharmaceutical company specializing in the development of protease inhibitors for the treatment of rare diseases. This chart reflects the progress of commercializing its scientific discoveries. The revenue growth at this stage is likely due to upfront payments from pharmaceutical industry partners.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-KalVista-Pharmaceuticals-KALV&v=1772513834556 "Sales chart per company employee KalVista Pharmaceuticals (KALV)")
Sales per employee in the market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company specializing in developing oral therapies for rare diseases such as hereditary angioedema (HAE). This chart shows how productive their research team is, measuring revenue (from partnerships) per researcher compared to competitors.
Sales per employee for the market as a whole
KalVista Pharmaceuticals (KALV) is a clinical-stage biotechnology company specializing in the development of drugs for the treatment of hereditary angioedema (HAE). The company has no commercial revenue yet. This chart illustrates a typical situation for an R&D company: the entire scientific staff is focused on development and testing, generating data rather than revenue.
Short shares by company, segment and market as a whole
Shares shorted by company KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals is a biotech company developing drugs to treat hereditary angioedema (HAE). The bearish sentiment shown in this chart reflects investor bets that its oral drug will not compete with existing injectable treatments or will not prove safe.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-KalVista-Pharmaceuticals-KALV&v=1772513834685 "Short Shares Chart for the Company KalVista Pharmaceuticals (KALV)")
Shares shorted by market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company developing an oral (tablet-based) drug for the treatment of hereditary angioedema (HAE). This indicator reflects skepticism. "Shorts" here are bets that their drug will not prove effective or will lose out to competitors.
Shares shorted by the overall market
KalVista Pharmaceuticals is developing drugs to treat a rare disease, hereditary angioedema. It's a highly specialized biotech company. When fear rises on this chart, investors don't want to understand complex diseases. They see a loss-making company and sell. KALV's success depends solely on science, despite the panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals (KALV) is a biotech company developing oral (tablet) drugs for the treatment of hereditary angioedema (HAE). This chart measures hype. It shows "overheated" (above 70) on positive trial data or "oversold" (below 30) on news of R&D setbacks or delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-KalVista-Pharmaceuticals-KALV&v=1772513834765 "RSI 14 indicator chart for the company's stock KalVista Pharmaceuticals (KALV)")
RSI 14 Market Segment - Pharma immune
KalVista (KALV) is a biotech company developing oral (tablet) treatments for the rare hereditary angioedema (HAE). The RSI_14_Seg for "Pharma-Immune" shows whether the biotech segment is overheated. The chart helps us understand: is KALV's volatility due to its R&D or general hype?
RSI 14 for the overall market
KalVista (KALV) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KALV (KalVista Pharmaceuticals)
KalVista Pharmaceuticals is a biotechnology company focused on developing oral (tablet form) therapies for the treatment of hereditary angioedema (HAE). This chart shows the analysts' average 12-month forecast, representing their collective bet on clinical trial success and commercial potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KALV-KalVista-Pharmaceuticals&v=1772513834810 "A chart showing analyst consensus forecasts for the expected stock price. KALV (KalVista Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price KALV (KalVista Pharmaceuticals)
KalVista (KALV) is a clinical-stage biotech focused on the rare disease hereditary angioedema (HAE). The company is developing an oral (tablet) drug. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in the success of this R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KALV-KalVista-Pharmaceuticals&v=1772513834830 "A chart showing the difference between the consensus forecast and the actual stock price. KALV (KalVista Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
KalVista Pharmaceuticals is a biotech company focused on developing oral (tablet) treatments for hereditary angioedema (HAE). This chart shows general expectations for the immunotherapy sector. It reflects whether experts believe there will be demand for convenient pills instead of injections.
Analysts' consensus forecast for the overall market share price
KalVista Pharmaceuticals is an R&D biotech focused on a rare disease (HAE - angioedema). They're burning through cash. This chart, reflecting the economic consensus, is their risk appetite. If the consensus is negative (downturn), investors flee cash-burning, pre-profit biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index KalVista Pharmaceuticals
KalVista is a biotech company focused on one goal: developing an oral (tablet-based) treatment for hereditary angioedema (HAE). This chart is a clear indicator of biotech expectations. It likely reflects their latest clinical trial data and market confidence in their chances of cracking this challenging market.
AKIMA Market Segment Index - Pharma immune
KalVista (KALV) is a clinical-stage biotech focused on HAE (a competitor to BioCryst, Pharvaris); the company is developing an oral (tablet) drug (Sebetralstat) for the treatment of acute attacks of HAE. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this niche (HAE) R&D focus (KALV) differentiate it from the average pharma company?
The AKIM Index for the overall market
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medications for the treatment of hereditary angioedema (HAE). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative company, committed to improving patients' lives, compares to overall economic trends.
